Pharma and Biotech Stocks On Sale



Pharma & Biotech

Subscriber Request Series: 5 Biotechnology (biotech) and 2 Pharmaceutical (pharma) Companies on sale. Each Tuesday I cover stocks that have been requested from our channel’s YouTube subscribers. This week I covered pharmaceutical giant Merck (MRK) and the much smaller company in transition Teva Pharmaceutical (TEVA). In the biotechnology subindustry I covered AbbVie (ABBV), Biogen (BIIB), Regeneron (REGN), Gilead (GILD), and Vertex (VRTX). Even in today’s very expensive stock market, there are many healthcare stocks that are on sale. Consequently, healthcare represents a fertile field for value-oriented investors seeking good investments that simultaneously provide a margin of safety. I believe that 6 of the 7 stocks I am covering this week fit that bill. Moreover, although one stock, Vertex, looks expensive, its price has been reverting to the mean torts fair value. As a result, patient investors might keep their eye on this stock as it gets closer and closer to attractive valuation.

FAST Graphs Analyze Out Loud Video on Pharma & BioTech Stocks:

Try FAST Graphs for FREE Today!

SUBSCRIBE to our YouTube Channel

Click here for our Research Articles

Disclosure:  Long ABBV, MRK, TEVA at the time of writing.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.

Unlock data on thousands of companies

Disclaimers: F.A.S.T. Graphs, Inc. is not a broker-dealer or a registered investment adviser. Under no circumstances does any information on constitute a recommendation to buy or sell a security, nor does it give investment advice. This is to include any publications or articles on is a research tool to be used by its subscribers in conjunction with the subscribers’ additional research and due diligence. The information on this site is in no way guaranteed for completeness or accuracy.